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Facilitating the implementation of clinical
technology in healthcare: what role does a
national agency play?
Gill Harvey1,2* , Sue Llewellyn2, Greg Maniatopoulos3, Alan Boyd2 and Rob Procter4
Abstract
Background: Accelerating the implementation of new technology in healthcare is typically complex and multi-faceted.
One strategy is to charge a national agency with the responsibility for facilitating implementation. This study examines
the role of such an agency in the English National Health Service. In particular, it compares two different facilitation
strategies employed by the agency to support the implementation of insulin pump therapy.
Methods: The research involved an empirical case study of four healthcare organisations receiving different
levels of facilitation from the national agency: two received active hands-on facilitation; one was the intended
recipient of a more passive, web-based facilitation strategy; the other implemented the technology without
any external facilitation. The primary method of data collection was semi-structured qualitative interviews with
key individuals involved in implementation. The integrated-PARIHS framework was applied as a conceptual lens to
analyse the data.
Results: The two sites that received active facilitation from an Implementation Manager in the national agency made
positive progress in implementing the technology. In both sites there was a high level of initial receptiveness to
implementation. This was similar to a site that had successfully introduced insulin pump therapy without facilitation
support from the national agency. By contrast, a site that did not have direct contact with the national agency made
little progress with implementation, despite the availability of a web-based implementation resource. Clinicians
expressed differences of opinion around the value and effectiveness of the technology and contextual barriers
related to funding for implementation persisted. The national agency’s intended roll out strategy using passive web-based
facilitation appeared to have little impact.
Conclusions: When favourable conditions exist, in terms of agreement around the value of the technology, clinician
receptiveness and motivation to change, active facilitation via an external agency can help to structure the
implementation process and address contextual barriers. Passive facilitation using web-based implementation
resources appears less effective. Moving from initial implementation to wider scale-up presents challenges and
is an issue that warrants further attention.
Keywords: Implementation, Technology, Facilitation, Insulin pump therapy, PARIHS, i-PARIHS
* Correspondence: gillian.harvey@adelaide.edu.au
1Adelaide Nursing School, University of Adelaide, Adelaide, SA 5005, Australia
2Alliance Manchester Business School, University of Manchester, Booth Street
East, Manchester M13 9SS, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Harvey et al. BMC Health Services Research  (2018) 18:347 
https://doi.org/10.1186/s12913-018-3176-9
Background
Accelerating the implementation of innovative technol-
ogy in healthcare is an international policy concern [1].
In the United Kingdom (UK) – the setting for the study
reported in this paper - the Department of Health pub-
lished a policy to promote innovation in the National
Health Service (NHS) in 2011 [2]. The policy set out a
strategy for realising the potential of innovation to im-
prove both quality and productivity; however, a subse-
quent evaluation indicated that progress towards
achieving the strategic objectives has been somewhat
patchy and slow [3]. This echoes the experience of
implementing other changes in clinical practice. Empirical
studies on knowledge translation, service improvement
and organisational change consistently demonstrate that
implementation is complex [4–7]. This has led to the de-
velopment of implementation theories and frameworks
that move beyond the notion of a linear pipeline [8] and
attempt to represent the interactive, context-specific pro-
cesses involved. Examples include Normalisation Process
Theory [9], the Consolidated Framework for Implementa-
tion Research [10], Practice-based Theories [11] and the
Promoting Action on Research Implementation in Health
Services Framework (PARIHS) [4, 12].
In this paper, our aim is to examine the facilitation
role of a national agency (the National Technology
Adoption Centre or NTAC) in England charged with ac-
celerating technology uptake in the NHS. We focus our
analysis on the technology of insulin pump therapy
(IPT) and study four organisations that received variable
types and levels of facilitation support from NTAC. To
frame the analysis, we apply the integrated-PARIHS
framework [13] as a theoretical lens to compare the dif-
ferent facilitation approaches and evaluate factors that
influenced implementation. Specifically, the paper aims
to address the following research questions:
1. Why are some organisations more successful than
others in implementing new technology? What
factors influence success?
2. How does a national agency providing external
facilitation support implementation?
3. How do active and passive facilitation strategies
compare in terms of influencing implementation?
Theoretical lens for analysis: The integrated-PARIHS
framework
PARIHS (Promoting Action on Research Implementa-
tion in Health Services) was one of the first frameworks
to explicitly recognise the complex, multi-faceted nature
of implementing changes in practice. First developed in
the late 1990’s [4], the framework has undergone 15 years
of evaluation and refinement [12, 14, 15], resulting in a
recently revised version known as the integrated-PARIHS
(i-PARIHS) framework [13]. The basic proposition of
i-PARIHS is that successful implementation results from
the facilitation of an innovation with the intended recipi-
ents of implementation in their local, organisational and
health system contexts. The key dimensions of i-PARIHS
are summarised in Table 1.
Facilitation represents the active ingredient of imple-
mentation. It comprises both facilitator roles and facilita-
tion processes that may be internal or external to the
implementation setting. Facilitation is concerned with en-
abling others (for example, by building knowledge, skills,
relationships and confidence to enact change) as opposed
to directing, telling, persuading or coercing people to
change. This requires a flexible and iterative approach to
assess and respond to barriers and enablers of implemen-
tation within the immediate and wider environment. We
use i-PARIHS as a theoretical framework to examine the
different facilitation strategies employed by NTAC, includ-
ing how they addressed factors relating to the innovation,
the recipients, and the local and wider context.
The technology of insulin pump therapy (IPT)
IPT is used in the treatment of Type 1 diabetes mellitus,
a condition where individuals require lifelong treatment
Table 1 The i-PARIHS framework [13]
Successful Implementation = Facilitation (Innovation, Recipients, Context)
Construct Key elements
Innovation Underlying knowledge sources (including research
evidence, clinical and patient experience)
Clarity
Degree of fit with existing practice
(compatibility vs contestability)
Degree of novelty
Relative advantage
Trialability
Recipients Motivation and readiness to change
Values and beliefs
Clinical consensus
Local opinion leaders
Skills and knowledge
Time and resources
Collaboration and team work
Power and authority
Context Leadership support
Culture
Past experience of innovation and change
Structure, systems and processes
Organisational priorities
Policy drivers
Incentives and mandates
Inter-organisational networks and relationships
Facilitation Network of facilitator roles (expert, experienced and novice)
Facilitation processes to enable implementation:
- Project management
- Quality improvement
- Team building and group process skills
- Influencing and negotiating
- Embedding and sustaining change
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with insulin. This can be administered in one of two
ways: multiple daily injections or a continuous subcuta-
neous infusion delivered by an insulin pump. IPT was
the subject of a technology appraisal by the National
Institute for Health and Care Excellence (NICE), which
is independent from but accountable to the Department
of Health in England. NICE guidance recommended IPT
as a clinically and cost effective treatment option for
adults and children with type 1 diabetes, where multiple
daily injections had failed, and for children under 12 if
multiple daily injections were not deemed practical or
appropriate [16]. NICE also produced a Commissioning
Guide to help health service commissioners plan and de-
liver services in line with the guidance [17]. This sug-
gested uptake of IPT for Type 1 diabetes should be 12%
of adults and 33% for children younger than 12 years
old. Existing data suggested IPT adoption in the UK was
much lower: around 1% in 2007 [18] and 3.7% in 2010
[19], in contrast to around 10% in other European coun-
tries [18]. It was this low uptake of IPT that prompted
its inclusion in NTAC’s work programme.
The NHS Technology Adoption Centre (NTAC)
NTAC was established in 2007 as a small organisation of
around seven staff, with a specific remit to tackle the
under-utilisation of clinical technologies within the NHS
in England. In 2013, after our study had finished, NTAC’s
role and function were transferred to NICE.
The NTAC approach involved identifying a priority list of
clinical technologies and then inviting NHS provider organi-
sations (known as Trusts) to self-nominate as ‘implementa-
tion sites’ for a particular technology. From sites that
applied, three or four were purposively selected and NTAC
worked directly with them to facilitate implementation. A
designated NTAC Implementation Manager acted as a fa-
cilitator to identify and engage with relevant stakeholder
groups, within and outside of the Trust. NTAC also selected
mentor sites – Trusts already implementing the technology
without NTAC facilitation – to provide additional guidance
and support to implementation sites. Learning from imple-
mentation and mentor sites was collated into an online
toolkit, known as a ‘How-to-Why-to’ guide (HTWT), which
included resources such as a template for developing a busi-
ness case and a costing model for the technology [20]. The
HTWT guide could be viewed as a passive facilitation strat-
egy that was intended to enable other NHS organisations to
implement the technology without direct, active facilitation
support from NTAC. In this way, the aim was to achieve
wider spread and scale-up of technology implementation.
Methods
Study design
The methodological approach was an empirical case
study of four organisations with an interest in implementing
IPT. This was one of three NTAC supported technologies
studied as part of a larger research project to explore bar-
riers to technology adoption in the NHS. The wider study
has been reported elsewhere [1, 11, 21]. We selected four
IPT sites, representing different levels of involvement with
NTAC and/or different types of facilitation. Two sites
(named Implementation Sites 1 and 2) received direct, ac-
tive facilitation from an NTAC Implementation Manager;
one site was a designated mentor (named Mentor Site) and
had previously implemented IPT without external facilita-
tion support; the fourth was a Trust that had applied to be
an implementation site but was not selected (named non-
NTAC site). This site was keen to implement IPT and, as
such, was typical of the organisations that NTAC was target-
ing with passive facilitation, via the HTWT guide. Table 2
provides background descriptions of the 4 sites.
Data collection
Data collection took place from July 2010 to July 2012
primarily using semi-structured, face-to-face interviews.
A total of 23 interviews (mostly individual, one group
interview) were conducted with key individuals involved
in implementing IPT, including physicians, nurse spe-
cialists, commissioners, procurement and business man-
agers. Three NTAC staff were interviewed: two Chief
Executives (one present at the start of the study and a
subsequent successor) and the Implementation Manager
for IPT. Interviews were around 60 min long and were
digitally recorded and transcribed for analysis. Table 3
summarises the interview sample by site and role.
Additional file 1 details the interview guide used
within the overall research project. Supplementary data
included background documentation, such as NTAC’s
selection of the IPT implementation sites and notes of
relevant meetings. To study the HTWT guides, we
filmed five clinical staff and one patient advocate using
the IPT guide in the presence of a research team mem-
ber, using a ‘think-aloud’ method [22]. Participants were
asked to articulate their thoughts on the content and
ease of use as they navigated the HTWT guide in real
time. The researcher asked reflective questions as appro-
priate. Finally, to gauge IPT uptake and awareness of
NTAC and the HTWT guides, we undertook a short sur-
vey of clinicians who were members of a diabetes network
with a special interest in IPT between May–July 2012
(Additional file 2). Table 4 summarises the data collection
strategies used to address the research questions.
Data analysis
Interviews were transcribed in full and, along with the
documentary evidence, were analysed inductively using
thematic analysis [23]. Core categories and themes were
identified for each participant and then compared within
and across the four cases. One member of the research
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team (GH) undertook the initial analysis. The wider pro-
ject team then reviewed emerging categories and
themes. Videos of participants using the HTWT guides
comprised the computer display as seen by the user and
a simultaneous shot of the user. A member of the re-
search team (AB) analysed each of the videos, noting
how the user navigated the HTWT guide and their ver-
bal and non-verbal responses. Observations across the
six videos were collated to produce key themes. We de-
rived descriptive statistics from the diabetic network sur-
vey which had a response rate of 28% (91 responses
from a sample of 320).
Results
We present our analysis through the i-PARIHS core
constructs: ‘Success’ of implementation; Innovation
(IPT)-related factors; Recipient-related factors; Context-
related factors; Facilitation-related factors.
‘Success’ of implementation
Of the two sites receiving direct, active facilitation from
NTAC, Implementation Site 1 increased the numbers of
patients using IPT during the timescale of the project
from around 9 to 53. In Implementation Site 2 the num-
bers using IPT stayed around 100, but this figure masked
the fact that some patients were newly started on pumps
and others were taken off because they did not meet the
NICE criteria for IPT.
Table 2 Description of the case study sites
Relationship with NTAC Description of case study site
Implementation site (1)
(Direct relationship, active facilitation)
NHS Trust providing specialist children’s services, commissioned from a wide range of
Primary Care Trusts (PCTs, 17 in total); differing arrangements in place in relation to
funding and contractual agreements.
Pressure to provide IPT had particularly been driven from the patient population
(children and parents); as a consequence the diabetic team were keen to become more
skilled and up to date in terms of providing pump services.
Implementation site (2)
(Direct relationship, active facilitation)
NHS Trust providing acute services; formed from the previous merger of two Trusts.
Diabetic services provided at two separate sites, one with a history of using IPT and the
other less receptive to the new technology.
No formalised processes or systems in place for managing the introduction of IPT at an
individual patient or service level prior to involvement with NTAC.
Commissioner (PCT) instrumental in applying for NTAC project.
Mentor site
(Direct relationship, no facilitation)
NHS Trust providing an integrated hospital, community and primary care diabetic service.
Originally applied to be part of the NTAC implementation project, but already well-advanced
in terms of the implementation of IPT; as a consequence the organisation was invited to act
as a mentor site for IPT.
The Trust had an internal manager with responsibility for commissioning, who facilitated the
relationship with the PCT to develop and negotiate contracts, an arrangement
that worked particularly well in the introduction of IPT.
Non-NTAC site
(No direct relationship, passive facilitation)
Specialist Diabetes Centre, hosted by an NHS Trust, having recently moved from a primary
to secondary care setting, as a result of the changes to commissioning in the NHS.
On account of its specialist status, the Centre dealt with a large number of commissioners
(PCTs) across a wide geographical area.
The introduction of IPT was led by a clinical academic, who had submitted an application to
become an NTAC implementation site. This application was unsuccessful; however, the
consultant and some of his colleagues had continued to try and develop their pump service
without input from NTAC.
Table 3 Interview sample by site and role
Site Role Number of
interviewees
Implementation site 1 Diabetic Consultant 1
Diabetic Specialist Nurse 2
Contracts Manager 1
Finance Manager 1
Implementation site 2 Diabetic Consultant 1
Diabetic Specialist Nurse 2
Project Manager (Dietitian) 1
Commissioner 1
Procurement Manager 1
Finance Manager 1
Mentor site Diabetic Consultant 1
Diabetic Specialist Nurse 1
Commissioning Manager 1
General (Service) Manager 1
Non-NTAC site Diabetic Consultant 4
Diabetic Specialist Nurse 1
Specialist Medical Trainee 1
Clinical Manager 1
NTAC Chief Executive 2
Implementation Manager 1
TOTAL 26
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The qualitative data indicate that the two implementa-
tion sites engaged actively in the implementation project
and made progress in developing their pump service. In-
terviewees spoke positively about the support they re-
ceived from the NTAC Implementation Manager, who
worked across both sites, and of their overall experience
of the project. The NTAC project was seen to have
provided a catalyst and a structure to move forward
on an issue that they were committed to improving.
Prior to their involvement with NTAC, the decision
to place patients on pump therapy had been mostly
consultant-led, with funding organised on an individ-
ual patient level. Working with NTAC had provided a
clear project management approach to address issues
such as developing an agreed care pathway for pump
patients, joint working with commissioners to address
funding arrangements, establishing a clear procure-
ment process for pumps, developing the necessary
nursing knowledge and skills to manage patients on
pumps, undertaking regular audits and introducing
multi-disciplinary pump clinics.
Both implementation sites and the mentor site were
involved in the development of the HTWT guides; how-
ever, the extent to which other Trusts asked for informa-
tion or advice following publication of the guide was
limited. It was viewed unlikely that the guide could sub-
stitute for the hands-on project management support
that NTAC provided.
I’d like to be able to show you some examples of where
this website has been used and someone’s done what
we have done, but my worry is that it’s quite hard
without that push from NTAC centrally. (Consultant,
Implementation Site 1).
This view was reinforced in the data from the non-
NTAC site where the pump service was similar to that
in the two implementation sites prior to their involve-
ment with NTAC. The service was championed by an
individual consultant but had no secure funding model
in place and lacked a clear infrastructure (such as spe-
cialist nurses) to develop it further. The lead consultant
was sceptical about how the HTWT guide would help to
address these issues:
I have to admit that I haven’t really looked at it and I
think that’s because I’ve got the impression, from other
pump professionals …. that, you know, it’s not going to
change my world for pump patients … no-one’s kind of
saying, okay you download that document, take it to your
Trust, you’ll be sorted. (Consultant 1, non-NTAC site)
The survey findings raise further questions about the
impact of the HTWT guide. 54% (n = 49) of the survey
respondents were aware of NTAC; of these, 63% (n = 31)
were aware of the HTWT guide on IPT. Only 13% (n = 6)
had used the guide to develop a business case for imple-
menting IPT and even fewer (8%, n = 4) had used it to
contact other organisations for information. Video data
from real-time users of the HTWT guide indicated diffi-
culties in navigating the online resource, partly due to the
way the content was organised and also because of the
slowness of the website. Some users felt that the content
portrayed the process of implementation as too complex,
time-consuming and technical.
In summary, sites that received direct facilitation sup-
port from NTAC reported the most positive outcomes
in terms of establishing or expanding their provision of
IPT, including setting up the necessary infrastructure
and funding arrangements. The same level of progress
was not observed in the non-NTAC site and the data in-
dicate limited impact of the HTWT guides beyond
awareness of their existence.
IPT-related factors
Some clinical staff expressed a view that issues relating
to the acceptability of pumps to patients could contrib-
ute to a lack of uptake. These included concerns about
how the pump might fit with a patient’s lifestyle or
how they felt about being permanently attached to a
pump; for others it was the requirements that went
alongside using a pump, for example, the need for
active self-management and regular blood glucose
monitoring.
There are a significant number who think about it
and then just don’t want even to take anything any
further. …… Having seen one, talked about it in
more detail, quite a number of them have come to
Table 4 Data collection strategies adopted to address the research questions
Research Question Data source
Interviews Documentation Video- recordings Survey data
1. Why are some organisations more successful than others in implementing
new technology? What factors influence success?
✓
2. How does a national agency providing external facilitation support implementation? ✓ ✓
3. How do active and passive facilitation strategies compare in terms of influencing
implementation?
✓ ✓ ✓ ✓
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the conclusion that it’s not for them .... (Consultant
2, Non-NTAC site)
For others the pump was seen to provide greater free-
dom to manage their diabetes, despite initial concerns
about the pump itself:
..... I think the patient experience is honestly amazingly
positive. Even people who have apprehensions about
going on the pump … generally speaking a few months
into pump they would not go back to injections.
(Specialist Medical Trainee, Non-NTAC site)
Despite evidence from clinical trials and a national
technology appraisal of IPT, some clinicians doubted
whether there was sufficient evidence to support the use
of IPT.
I’m not even a hundred per cent sure about the proven
clinical benefits. If you … do the proper randomised
controlled trial, pump versus intensive therapy with
an equivalent amount of input from health care
professionals, you don’t get a great difference in HbA1c
[a measure of average blood sugar levels] or in anything
else. You might get a difference in patient satisfaction in
favour of a pump, but that’s in folk who want to go onto
the pump. So I think sometimes the benefits of pumps
are a bit overstated. (Consultant 2, Non-NTAC Site)
This was in contrast to the other sites where IPT was
widely regarded as a ‘proven technology’.
I suppose, on the surface, it looks expensive but there’s
then the evidence.... that’s why NTAC have taken it on
..... because the improvement of the blood result [and]
…. in preventing complications ...[it] is a proven
technology for improving progress with [diabetic]
complications. (Diabetic Specialist Nurse 1,
Implementation Site 2).
A particular issue was raised about the wording of
the NICE guidance, which indicated IPT as the rec-
ommended treatment option when multiple daily
injections had failed (in adults) or were seen as im-
practical or inappropriate (in children). This created
an interpretation of IPT as a ‘treatment of failure’,
rather than a clinically effective option that should
be available to all.
…. NICE guidance is geared to pump use being used as
a treatment of failure. So if you fail with your multiple
daily injections, i.e. you’ve still got poor control, or
you’ve still got low blood glucose. It’s a negative process
... … Why is pump therapy used as the treatment of
failure, if it’s supposedly the best treatment? (Specialist
Medical Trainee, Non-NTAC site)
Recipient-related factors
As already noted, considerable divergence of opinion
was apparent. This included differing views around who
was responsible for driving increased use of IPT. Some
clinical staff felt that patients were responsible for the
growth of the technology:
We are very good at being ahead of our patients in
what they know about either their condition or their
treatment plan or their medications. But with insulin
pumps, there was a feeling that we were only just one
step ahead of our patients …… the patients were
asking for them and we were saying, “Oh, hang on
a minute. We’re not so sure that we have the skills
and knowledge to facilitate this for you.” (Diabetic
Specialist Nurse 1, Implementation Site 1)
Other clinicians did not perceive a significant patient-led
demand for pumps:
One of the things that I have noticed when I’ve
been to meetings and so on elsewhere that some of
the people say patients ask for pump therapy. It
doesn’t happen in my experience very much. .... it
tends to be us that says, “well actually I think you
might benefit, would you consider a pump?”
(Consultant, Implementation Site 1)
Clinician related factors appeared particularly influen-
tial in the decision to use IPT. The motivation of indi-
vidual consultants was especially important.
.... we have always been a forward looking trust I
think, although we are only a district general
hospital I do think that we have a philosophy …..
that our patients should not miss out on any
treatment that could be of benefit to them (Consultant,
Implementation Site 1).
The motivational issue also worked in reverse and
created a barrier to implementation if individual clini-
cians were wary or resistant to use the technology. In
some cases, this related to a negative experience with
a pump:
I’m sceptical because I’ve seen the good things and I’ve
also seen the bad things about pumps. Like the girl we
admitted last weekend …. who nearly died … we
hadn’t put her on a pump, she was put on a pump
elsewhere and she didn’t self-manage properly.
(Consultant 2, Non-NTAC site)
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In other cases, resistance was tied up with local polit-
ics and personality differences:
…. one of the … internal barriers to implementation …
one individual in particular who was asked to be
involved …. but if it isn’t his project he doesn’t
want to know and he has done quite a few things
to try and sabotage the [project]. (Project Manager,
Implementation Site 2)
Alongside the motivational (‘want to’) factors, issues
relating to capability and capacity (‘can do’ factors) to
provide an IPT service were also identified. These in-
cluded the need for staff and patient education:
When a patient goes on a pump, initially, it is...very
time-consuming, the patient needs lots of education ....
the thing about the pump is, whether it works or not,
depends on patients’ self-management. (Diabetic
Specialist Nurse 2, Implementation Site 1)
Some clinicians expressed a view that the additional
input required to care for pump patients could actually
disadvantage non-pump patients:
…. in [this organisation], we expend a great deal of
health care time with the small number of people who
are on pumps and that is to the detriment of people
who are not on pumps. We have a limited number of
physicians, nurses, dieticians and if they’re working
with pumps, it means that they’re not working with
our other non-pump population. (Consultant 2,
Non-NTAC Site)
Context-related factors
Beyond the patient and clinician level, there were factors
relating to the organisation and delivery of healthcare that
impacted on IPT provision. These included politics and
culture at a local level, alongside organisational and sys-
tem level issues related to funding and commissioning
new technologies. Introducing IPT required a significant
upfront investment to purchase pumps, alongside the ne-
cessary infrastructure to educate and support staff and pa-
tients, including the appointment of specialist pump
trained nurses. How this funding was obtained varied
considerably. Historically, some clinicians had funded
IPT through their own research budgets. However,
the publication of the NICE guidance had placed a
requirement on commissioners of health services to
fund IPT, which was seen to be an important driver
for implementation.
PCTs [Primary Care Trusts, the organisations responsible
for commissioning healthcare in the English NHS at the
time of the study] …. have to be seen to be following NICE
guidance, so I know it’s a time of austerity and the PCTs
have other priorities, but a trust should always play the
NICE guidance card and say, look you know, that’s why
we’ve got NICE guidance because it’s the best outcomes for
this group of patients. (Diabetic Specialist Nurse,
Mentor Site)
As indicated in Table 2, each of the sites had differing
arrangements with their commissioners and this influ-
enced the ease with which they could implement IPT.
The closer and less complicated the relationship, the
smoother the process appeared to be:
… it’s been driven primarily by the PCT because once I
became involved, I did actually start trying to structure
it and say, you know, let’s look at it in a more
comprehensive way; rather than just clinicians thinking
this is a great thing to do, without any thought about
how we’re going to pay for it. (Commissioner,
Implementation Site 2)
This was in contrast to Implementation Site 1 that
worked with many different commissioning organisa-
tions, creating an added complication because “they all
have a different way of working” (Diabetic Specialist
Nurse 2, Implementation Site 1). NTAC placed a lot of
emphasis on helping organisations navigate issues re-
lated to funding IPT, through providing help with devel-
oping business cases and producing costing models.
However, interviewees raised concerns that the costs re-
lated to establishing an IPT service, namely a nurse spe-
cialist and patient education, typically fell outside PCT
funding arrangements and had to be directly absorbed
by the provider organisation.
Facilitation-related factors
Here we focus on the two different strategies (either
active or passive) that NTAC employed to facilitate im-
plementation. The initial active facilitation approach in-
volved an NTAC Implementation Manager working as
an external facilitator and using project management
methods to structure the implementation process. This
was followed by a more passive facilitation strategy that
relied on the HTWT guide, an interactive web-based re-
source, without direct facilitator input. For the two im-
plementation sites, the NTAC facilitator played a key
role. Whilst the sites were motivated to implement IPT,
the external facilitation provided by NTAC acted as a
catalyst and helped to guide the implementation process
through providing a formal project management struc-
ture and developing the systems that were needed to
support the use of the technology.
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They [NTAC] were phenomenally helpful. We knew
where we wanted to be, but weren’t sure of the map to
use to get us there..... NTAC were really good in helping
us to get the people in the room who needed to be in the
room, to have the right conversations. Project
management – I think that’s what we really lack
and what they did really well. (Diabetic Specialist
Nurse 1, Implementation Site 1)
This strong project management focus was in keeping
with how NTAC perceived their role in implementation,
although interestingly there was no agreed framework to
guide their approach.
There was no model. There was no laid out plan of
how to do it ... [the chief executive] wanted people who
could come in, who were experienced, who had enough
seniority to push this change forward. To be in that
environment, you needed to have some initiative of
your own ... [the chief executive] said to me, ‘I don’t
care how you do it ... Here’s your budget. Now go away’
... I had a blank piece of paper. (NTAC Implementation
Manager)
Whilst NTAC provided a welcome project manage-
ment approach, their involvement was perceived to be at
the planning stage of the implementation process. Im-
plementation Site 2 had an internal project manager
who was responsible for the ongoing implementation; in
Implementation Site 1 it was less clear where this re-
sponsibility lay. The active process of facilitation, with
an individual in a designated facilitator role, was in sharp
contrast to the planned process for rolling out imple-
mentation of IPT through the HTWT guide on an inter-
active website. Respondents expressed considerable
doubt over whether this more passive approach could
substitute for the hands-on facilitation provided by the
NTAC Implementation Manager.
Discussion
From the findings it is apparent that evidence perceived
to be ‘strong’ from a traditional healthcare evaluation
perspective (i.e. confirmed by multiple randomised con-
trolled trials, systematic reviews and technology ap-
praisal) could be subject to different interpretations at a
patient and clinical level. This was clearly so in relation
to IPT despite the NICE guidance. There was a juxta-
position of evidence of effectiveness with questions of
acceptability or appropriateness, for example, whether
patients wanted to wear a pump or whether they met
the criteria for self-management. In other situations, the
evidence of effectiveness was itself the focus of debate
and individual clinician experience could cast doubt on
its robustness or relevance, as was the case where a
medical consultant had witnessed a critical incident of a
patient using IPT. This reinforces other studies that
demonstrate the contestability of research evidence
[5, 24–26]. It also illustrates the complex inter-
relationship between the innovation and the intended
targets of innovation, relationships that directly influence
and shape the innovation journey [27, 28]. Additionally, it
demonstrates the mediating role of context, not just at the
immediate level of implementation but at the policy,
systems and organisational level, where the complexities
associated with the business of healthcare delivery (for ex-
ample, funding, commissioning, procurement) are import-
ant determinants of whether and how easily a new
technology can be implemented [11].
What do the findings tell us about the role of a na-
tional agency such as NTAC with a remit to function as
a facilitator of implementation? They suggest that NTAC
did play a central role in facilitating the implementation
of IPT in the two sites they worked with. At both sites a
set of circumstances were observed that created a high
level of receptiveness to IPT. The evidence underpinning
the technology was well accepted by clinicians, managers
and commissioners and strengthened by formal endorse-
ment through NICE. In Implementation Site 1, this was
further enhanced by the patient/parent push to have ac-
cess to the technology. Thus there was a clear alignment
of stakeholders around the innovation, in terms of its
relevance, acceptability and effectiveness. This created a
strong motivation to introduce IPT, which is recognised
as an important element of readiness to change [29].
However, the capacity to change was less apparent as
the organisations were generally uncertain about how to
approach implementation. This is where the active facilita-
tion provided by NTAC was beneficial, with the NTAC
Implementation Manager helping to bring key stakeholders
together, providing a structured project management ap-
proach and addressing system issues related to funding,
commissioning and procurement of the technology.
In contrast the non-NTAC site demonstrated less
agreement around the innovation, in terms of whether it
was safe or had a strong enough evidence base to sup-
port its use. One clinician was extremely keen to intro-
duce pump therapy but did not have the full support of
colleagues, management or the wider multi-disciplinary
diabetes team. Arrangements for funding IPT were un-
clear and progress with implementing the technology
was limited. Whether the NTAC approach would have
worked as easily or smoothly in such a setting is debat-
able, as here it was not simply a case of introducing a
project management structure and process. Knowledge
could be seen to be ‘at stake’ [30] as professionals within
the clinical team held opposing views and interpreted
the evidence for IPT in different ways. Consequently,
more significant boundaries to implementation existed,
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likely requiring a more intensive and tailored approach
to facilitation, with greater attention to negotiating the
differences of opinion [30, 31].
The mentor site did not work with NTAC or an exter-
nal facilitator to introduce IPT. However, there was clear
evidence of facilitating roles and processes within the or-
ganisation that were key to enabling implementation.
The organisation had well established networks and rela-
tionships across acute and primary care and could be de-
scribed as an early adopter [27] as they had introduced
IPT sometime before NICE guidance was issued. This
integrated way of working was supported by having a
manager based in the acute service with an explicit re-
sponsibility for working with primary care commis-
sioners to agree contracts. This manager effectively
functioned as an internal facilitator of implementation
and the financial and system level barriers that were
problematic in other organisations did not present a
major obstacle. This highlights the potential importance
of an internal facilitator to embed and sustain imple-
mentation, a role that the designated project manager in
Implementation Site 2 appeared to fulfil.
The i-PARIHS framework suggests that the dynamic
relationships between the innovation, intended recipi-
ents and the context are best handled through the active
medium of facilitation, defined in terms of facilitator
roles and facilitation processes. The findings of our study
largely support this proposition, highlighting the import-
ance of active facilitation via an individual functioning in
a facilitator role. NTAC’s strategy for wider roll-out of
IPT which involved moving from direct support by a
designated facilitator to an online resource (in other
words, from active to passive facilitation) met with lim-
ited success, suggesting that some form of human
agency facilitating implementation is important. How-
ever, exactly what nature, form and function the facilita-
tion process should take merits further exploration. For
example, is a project management approach to facilita-
tion (as adopted by NTAC) particularly suited to
organisations with a high level of initial readiness and
receptiveness to innovation? And is this sufficiently
flexible where there are less receptive conditions? Alter-
natively, when there is an extremely favourable set of cir-
cumstances (as in the case of the mentor site) is an
environment where internal managers function in a
facilitative way sufficient? These are all interesting and
important areas for further investigation, particularly in
the context of debates about whether we are over-
engineering implementation strategies when simple and
cheaper alternatives would suffice [31, 32]. Further ques-
tions relate to how organisations with a national remit
for implementation can best fulfil their role if facilitation
via human agency is required. From a resource perspec-
tive, it may be more appropriate for agencies such as
NTAC to work through local networks (such as the
Diabetic Network involved in the survey) to develop and
cascade the facilitation skills needed to implement, sus-
tain and spread new technology, rather than providing
direct facilitator support to a small number of organisa-
tions [33].
Conclusions
This paper has analysed an empirical case study of four
organisations attempting to implement IPT to illustrate
the interplay of factors that influence the implementa-
tion of clinical technology in healthcare and the role of a
national agency in facilitating the process. Through the
conceptual lens of the i-PARIHS framework, the findings
indicate that when favourable conditions for implemen-
tation exist, in terms of agreement around the
innovation to be implemented and clinical receptiveness
and motivation to change, a national agency can employ
a combination of an external facilitator and project man-
agement methods to initiate implementation and address
contextual barriers relating to funding and commission-
ing new technology. The extent to which such an ap-
proach would achieve similar results in a less receptive
environment is unclear. There is also the important issue
of how a national agency can best facilitate the spread of
innovation since moving from active to more passive
methods (in this case, direct support from Implementa-
tion Managers to an online resource) appeared to have
little impact.
We acknowledge that a potential limitation is our
focus on the study of a single technology, which may
limit the transferability of the findings to the wider chal-
lenge of technological innovation in healthcare. Equally
we recognise that our findings reinforce similar issues
identified in other studies of technology implementation
and uptake in healthcare [34, 35]. We believe there is
merit in applying implementation theories to inform this
field of study, both prospectively and retrospectively. In
particular, we would suggest further examination of the
facilitation roles and processes needed to work with or-
ganisations that are reluctant or late adopters of new
technology, including strategies that can be scaled up in
both an effective and efficient way.
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